Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial

Bigelow, 2012, Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose–effects and time-course, Drug Alcohol Depend., 123, 57, 10.1016/j.drugalcdep.2011.10.018 Brenna, 2021, 108667 Brorson, 2013, Drop-out from addiction treatment: A systematic review of risk factors, Clin. Psychol. Rev., 33, 1010, 10.1016/j.cpr.2013.07.007 Comer, 2020, Transition of patients with opioid use disorder from Buprenorphine to extended-release naltrexone: a randomized clinical trial assessing two transition regimens, 29, 313 Comer, 2006, Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial, Arch. Gen. Psychiatry, 63, 210, 10.1001/archpsyc.63.2.210 Gaulen, 2022, The predictive value of degree of preference for extended-release naltrexone for treatment adherence, Opioid Use, Relapse., 28, 56 Guliyev, 2022, Predictors of relapse to alcohol and substance use: are there any differences between 3 and 12 months after inpatient treatment?, J. Psychoactive Drugs, 54, 358, 10.1080/02791072.2021.1976887 Krupitsky, 2013, Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness, Addiction, 108, 1628, 10.1111/add.12208 Kunøe, 2010, Challenges to antagonist blockade during sustained-release naltrexone treatment, Addiction, 105, 1633, 10.1111/j.1360-0443.2010.03031.x Kunøe, 2016, Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX), BMC Pharmacol. Toxicol., 17, 1, 10.1186/s40360-016-0061-1 Latif, 2018, Anxiety, depression, and insomnia among adults with opioid dependence treated with extended-release naltrexone vs buprenorphine-naloxone: A randomized clinical trial and follow-up study, JAMA Psychiatry Lee, 2017, Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial, Lancet, 391, 309, 10.1016/S0140-6736(17)32812-X Moe, 2022, Is the relapse concept in studies of substance use disorders a ‘one size fits all’concept? A systematic review of relapse operationalisations, Drug. Alcohol. Rev., 41, 743, 10.1111/dar.13401 Norwegian Institute for Alcohol and Drug Research, 2015 Nunes, 2019 Opheim, 2021, Risk of relapse among opioid-dependent patients treated with extended-release naltrexone or buprenorphine-naloxone: A randomized clinical trial, Am. J. Addict., 30, 453, 10.1111/ajad.13151 Rudd, 2016 Sobell, 1992 Solli, 2019, Availability of extended-release naltrexone may increase the number of opioid-dependent individuals in treatment: extension of a randomized clinical, Trial., 25, 303 Solli, 2018, Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a nine-month follow-up to a three-month randomized trial, Addiction, 113, 1840, 10.1111/add.14278 Solli, 2020, Adapting treatment length to opioid-dependent individuals’ needs and preferences: A 2-year follow-up to a 1-year study of extended-release naltrexone, Addiction, 116, 2084, 10.1111/add.15378 Strang, 2020, Opioid use disorder, Nature 6, Article number: 3 Tanum, 2017, Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: A randomized clinical noninferiority trial, JAMA Psychiatry, 74, 1197, 10.1001/jamapsychiatry.2017.3206 UNODC, 2015 Volkow, 2014, Medication-assisted therapies--tackling the opioid-overdose epidemic, N. Engl. J. Med., 370, 2063, 10.1056/NEJMp1402780